4883.T
Modalis Therapeutics Corporation
グロース · 医薬品 · 医薬品 · JP
JPY 35.00
+2.94%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 245.5M | 267.8M | 40.0M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 219.3M | 231.8M | 245.5M | 267.8M | 242.0M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 219.3M | 231.8M | 245.5M | 267.8M | 242.0M |
| Cost and Expenses | — | — | 1.6B | 2.6B | 2.1B |
| Operating Income (EBIT) | (1.9B) | (2.2B) | (1.3B) | (2.4B) | (2.1B) |
| Non-Operating | |||||
| Interest Income | 4.8M | 3.8M | 102.0K | 25.0K | 57.0K |
| Interest Expense | 4.3M | 2.8M | 3.9M | 4.4M | 4.8M |
| Net Interest Income | 479.0K | 1.0M | (3.8M) | (4.4M) | (4.8M) |
| Other Non-Op Income/Expense | 102.1M | 63.2M | 34.6M | 18.9M | 67.4M |
| Non-Operating Income (excl Interest) | 98.7M | 77.9M | 64.5M | 39.8M | 76.9M |
| EBT (Pre-Tax Income) | (1.8B) | (2.2B) | (1.3B) | (2.4B) | (2.7B) |
| Income Tax Expense | 1.7M | 1.5M | 965.0K | 1.2M | (4.3M) |
| Bottom Line | |||||
| Net Income | (1.8B) | (2.2B) | (1.3B) | (2.4B) | (2.7B) |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.8B) | (2.2B) | (1.3B) | (2.4B) | (2.7B) |
| Per Share | |||||
| Basic EPS | (¥24) | (¥28) | (¥29) | (¥77) | (¥93) |
| Diluted EPS | (¥24) | — | — | — | — |
| Revenue Per Share | — | — | ¥5 | ¥9 | ¥1 |
| Shares | |||||
| Basic Shares Outstanding | 88.9M | 77.3M | 46.1M | 31.0M | 29.1M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | — | — | (2.4B) | (1.9B) |
| D&A | — | — | — | 731.0K | 123.7M |
| EBIT | (1.9B) | (2.2B) | (1.3B) | (2.4B) | (2.1B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026